Insider Selling: Kura Oncology (NASDAQ:KURA) Insider Sells $309,621.50 in Stock

Posted by Francis Steltz on Oct 2nd, 2026

Kura Oncology, Inc. (NASDAQ:KURA – Get Free Report) insider Mollie Leoni sold 28,802 shares of the company’s stock in a transaction dated Tuesday, September 29th. The stock was sold at an average price of $10.75, for a total value of $309,621.50. Following the completion of the sale, the insider owned 141,095 shares of the company’s stock, valued at approximately $1,516,771.25. The trade was a 16.95% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Mollie Leoni also recently made the following trade(s):

On Monday, September 28th, Mollie Leoni sold 12,448 shares of Kura Oncology stock. The shares were sold at an average price of $10.50, for a total value of $130,704.00.

Kura Oncology Trading Down 0.6%

Shares of NASDAQ:KURA opened at $10.65 on Friday. The stock has a 50 day moving average of $11.23 and a 200 day moving average of $10.19. The company has a market cap of $947.42 million, a PE ratio of -3.16 and a beta of 0.47. Kura Oncology, Inc. has a 12-month low of $7.36 and a 12-month high of $13.90. The company has a current ratio of 4.73, a quick ratio of 4.71 and a debt-to-equity ratio of 0.12.

Kura Oncology (NASDAQ:KURA – Get Free Report) last released its earnings results on Wednesday, August 12th. The company reported ($0.77) EPS for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.11. Kura Oncology had a negative net margin of 384.30% and a negative return on equity of 207.18%. The company had revenue of $20.87 million for the quarter, compared to analysts’ expectations of $20.16 million. As a group, equities research analysts expect that Kura Oncology, Inc. will post -3.25 EPS for the current year.

Wall Street Analyst Weigh In

KURA has been the topic of a number of recent analyst reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Kura Oncology in a report on Thursday, June 4th. Raymond James Financial set a $24.00 price target on Kura Oncology in a report on Monday, August 24th. Wedbush lifted their price objective on shares of Kura Oncology from $36.00 to $38.00 and gave the company an “outperform” rating in a research report on Thursday, August 13th. Citizens Jmp reissued a “market outperform” rating and issued a $24.00 target price on shares of Kura Oncology in a report on Monday, August 24th. Finally, Sanford C. Bernstein set a $24.00 target price on shares of Kura Oncology in a research note on Monday, June 15th. Eleven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Kura Oncology currently has a consensus rating of “Moderate Buy” and a consensus target price of $25.69.

Check Out Our Latest Stock Report on Kura Oncology

Key Kura Oncology News

Here are the key news stories impacting Kura Oncology this week:

Positive Sentiment: JPMorgan initiated coverage of Kura Oncology with an “overweight” rating and a $30 price target, implying substantial upside from recent trading levels. The firm views Kura as a promising precision-cancer-medicine developer, particularly because of its menin-inhibitor platform and lead program, ziftomenib, for genetically defined acute myeloid leukemia. JPMorgan Kura Oncology rating article
Positive Sentiment: CNBC highlighted JPMorgan’s view that KURA could nearly triple, reinforcing the potential valuation impact of successful clinical and regulatory execution. The bullish outlook is particularly important for a biotechnology stock trading below the average analyst target of approximately $25.40. CNBC Kura Oncology analyst outlook
Neutral Sentiment: Kura’s financial position remains relatively liquid, with a reported quick ratio of 4.71 and current ratio of 4.73, but the company remains unprofitable and analysts expect a significant full-year loss. That means the stock’s valuation continues to depend heavily on clinical progress rather than current earnings.
Negative Sentiment: Multiple insiders, including executives Kathleen Ford, Brian Powl, Mollie Leoni, Thomas Doyle and Teresa Bair, sold shares in late September and October 1. The reported transactions represent roughly 97,000 shares and more than $1 million in proceeds, creating a potential near-term overhang. The sales do not necessarily indicate deteriorating business prospects, since the insiders retained meaningful holdings, but they may weigh on investor confidence. Kura Oncology insider sales

Institutional Trading of Kura Oncology

Large investors have recently added to or reduced their stakes in the company. Tidal Investments LLC bought a new position in shares of Kura Oncology during the 2nd quarter valued at approximately $1,029,000. WINTON GROUP Ltd grew its holdings in shares of Kura Oncology by 26.2% in the second quarter. WINTON GROUP Ltd now owns 13,000 shares of the company’s stock valued at $143,000 after purchasing an additional 2,700 shares in the last quarter. Integrated Wealth Concepts LLC purchased a new position in shares of Kura Oncology in the second quarter valued at $159,000. IFP Advisors Inc increased its position in Kura Oncology by 136.5% in the second quarter. IFP Advisors Inc now owns 2,542 shares of the company’s stock worth $28,000 after purchasing an additional 1,467 shares during the last quarter. Finally, Allworth Financial LP increased its position in Kura Oncology by 148.4% in the second quarter. Allworth Financial LP now owns 10,326 shares of the company’s stock worth $113,000 after purchasing an additional 6,169 shares during the last quarter.

Kura Oncology Company Profile

(Get Free Report)

Kura Oncology, Inc is a biopharmaceutical company focused on developing precision medicines for the treatment of cancer. The company’s research programs target specific genetic and molecular abnormalities that contribute to tumor growth, with an emphasis on hematologic malignancies and selected solid tumors.

Kura’s leading program has been ziftomenib, an oral, selective menin inhibitor being developed for genetically defined forms of acute myeloid leukemia, including cancers with NPM1 mutations or certain KMT2A rearrangements.